Solutions
Online Inquiry

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

Data Management & Biostatistics for Weight Loss Studies

Inquiry

Overview

In the high-stakes world of weight loss therapeutics, your data is only as strong as the infrastructure supporting it. Whether you are navigating a phase I dose-escalation study or a massive multi-center randomized controlled trial (RCT), the complexity of metabolic data—ranging from simple BMI to high-dimensional omics—requires a specialized touch. At Protheragen, we don't just manage numbers; we curate them. Our data management & biostatistics service guarantees a statistically sound study design, secure and GCP-compliant data collection, and a final analysis that is resilient to the evaluations of global regulatory bodies such as the FDA and EMA.

Turning Metabolic Noise into Regulatory Music - Precision Data Solutions

Protheragen provides a seamless transition from raw clinical observations to polished, submission-ready datasets. We specialize in the unique challenges of obesity research, such as high attrition rates and complex covariate adjustments.

Database Construction & Data Management Service

A study is only as good as its data management plan (DMP). We design and build customized electronic data capture (EDC) systems tailored for metabolic endpoints. Our focus is on data integrity, utilizing real-time validation checks to capture everything from patient behavioral logs to complex laboratory biomarkers. We ensure your database is a fortress of clean, traceable information.

Statistical Analysis & CDISC Transformation Service

Raw data speaks many languages, but regulators only speak CDISC. We specialize in transforming clinical data into SDTM and ADaM formats. Our biostatisticians develop rigorous statistical analysis plans (SAP) that employ advanced modeling—such as mixed-effects models and multiple imputation—to account for the complexities of long-term weight loss trends and missing data.

Comprehensive Clinical Research Solutions

Protheragen provides an end-to-end data ecosystem that prioritizes clinical logic and mathematical precision. Our team bridges the gap between the clinic and the computer, ensuring that the why of your study is always reflected in the how of your data. We go beyond simple mean changes, offering deep-dive analyses into metabolic responders vs. non-responders, cardiovascular risk correlations, and patient-reported outcomes. Our infrastructure is built to support a variety of innovative designs, including Adaptive Dose Escalation and Pragmatic Clinical Trials.

Database Construction & Data Management Service
Statistical Analysis & CDISC Transformation Service
Project Management & Quality Control Service
Clinical Sample & Document Management Service
Safety Monitoring & Signal Management Service
Risk Control & Aggregate Reporting Service

Workflow

Protheragen utilizes a standardized, highly iterative workflow to ensure data quality at every milestone. Our process is designed to catch errors at the point of entry rather than at the point of analysis, significantly reducing the clean-up time required at the end of a study.

Process of our data management & biostatistics services for weight loss studies. (AI-Protheragen)

Connect with Therapeutic Area Experts to Evaluate Your Development Pipeline.

Applications

  • Sample Size Calculation & Power Analysis

Ensuring your study is neither underpowered (leading to missed signals) nor overpowered (leading to unnecessary costs).

  • Handling of Missing Data (Estimand Framework)

Applying the principal estimand approach to account for treatment discontinuation or rescue medication, ensuring the Intention-to-Treat (ITT) analysis remains robust and conservative.

  • Advanced Metabolic Modeling

Utilizing analysis of covariance (ANCOVA) and mixed-effects model for repeated measures (MMRM) to adjust for baseline imbalances and explore the longitudinal trajectory of weight loss over 52+ weeks.

  • Integrated Safety Databases

Building centralized safety repositories that sync with our Risk Control & Aggregate Reporting Service to provide a real-time view of Adverse Event (AE) trends across multiple trial sites.

Advantages

Regulatory-Grade Compliance

Our systems and processes are fully 21 CFR Part 11 compliant, ensuring that every data point has a clear audit trail and is ready for a formal inspection.

Obesity-Specific Expertise

We understand the nuances of weight loss data, from the significance of a 5% weight reduction threshold to the statistical handling of rebound effects during follow-up phases.

CDISC-First Approach

By designing our databases with CDISC in mind from day one, we eliminate the costly and time-consuming back-mapping usually required before an NDA or BLA submission.

Seamless Tool Integration

Our data platforms can ingest information from various sources, including wearables, mHealth apps, and central labs, providing a holistic view of the patient's metabolic journey.

Publication Data

Title: Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial.

Journal: Nature medicine, 2025.

DOI: https://doi.org/10.1038/s41591-025-03774-9

Summary: In this study, researchers conducted a 6-week phase 1 randomized trial to evaluate tirzepatide's effects on ingestive behavior in 114 adults with overweight or obesity. A multi-modal data capture framework was implemented, integrating controlled energy intake assessments, validated behavioral questionnaires (VAS, FCI, FCQ-S, PFS, Eating Inventory, BIS), and BOLD fMRI. The primary endpoint was analyzed using ANCOVA, with MMRMs applied to longitudinal secondary outcomes, ensuring rigorous biostatistical handling of complex metabolic and neuroimaging datasets. With an 89% completion rate and standardized quality controls, the study demonstrated that tirzepatide reduced energy intake by 524.6 kcal versus placebo at week 3 while modulating brain activation in appetite-regulating regions. This work highlights how structured data management and advanced statistical analysis generate regulatory-ready evidence for anti-obesity therapeutics.

Fig.1 Trial profile and study design of the phase 1 tirzepatide trial showing participant screening, randomization, and completion flow across three treatment groups. (Martin, et al., 2025) Fig. 1 Trial profile and study design. (Martin, et al., 2025)

Customer Review

Precision in Analysis
"Protheragen's biostatisticians didn't just run the numbers; they helped us redefine our endpoints to better capture the metabolic benefits of our candidate. Their CDISC mapping was flawless."
—Dr. L.S., Chief Scientific Officer

Reliable Data Infrastructure
"The EDC system Protheragen built for our multi-center trial was intuitive for our sites and gave us real-time visibility into our safety data. It made the database lock process incredibly smooth."
M.T., Director of Clinical Data Management

Submit Project Details for Comprehensive Clinical Strategy Consultations with Experts.

Frequently Asked Questions

  1. Why is 'Multiple Imputation' important in obesity trials?

    Obesity studies often have higher dropout rates than other fields. Multiple Imputation allows us to statistically account for missing data points without introducing the bias that comes from simply ignoring patients who left the study.

  2. How do you ensure data quality and consistency across multiple trial sites?

    We deploy centralized EDC platforms with real-time edit checks and automated validation protocols that flag discrepancies at the point of entry. Our dedicated data managers perform ongoing central monitoring and targeted source data verification (SDV), ensuring uniform, audit-ready datasets across all geographic locations.

  3. Can you convert legacy data into CDISC format?

    Yes. Through our statistical analysis & CDISC transformation service, we can take datasets from older trials and map them to current SDTM/ADaM standards for use in integrated safety summaries or new submissions.

Protheragen is committed to ensuring that the story your data tells is accurate, compliant, and compelling. Whether you are launching your first study or preparing for a final regulatory push, our team is here to support you. Contact us today to discuss the statistical framework for your weight loss study.

Reference

  1. Martin, C.K.; et al. Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial. Nature medicine. 2015, 31(9), 3141-3150. (CC BY 4.0)

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Related Disease Solutions
Inquiry
0
Inquiry Basket

Copyright © Protheragen. All rights reserves.